Bone marrow-derived mesenchymal stem cells combined with cord blood for treatment of graft failure

The aim of this study is to evaluate the efficacy and safety of use of expanded allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) and BM-MSCs combined with cord blood (CB) for treatment of post-autologous hematopoietic stem cell transplantation (auto-HSCT) patients with graft failure. The results of the clinical trial indicate that both MSC and MSC+CB treatments effectively treat engraftment failure and do not result in graft versus-host disease or increase the risk of tumor recurrence. The MSCs+CB regimen had a greater effect on neutrophil reconstruction.